Vertex Pharmaceuticals (Nasdaq: VRTX) presented additional data from cohort 2 of the Phase 2 VX-809 (lumacaftor/ivacaftor) trial in F508del cystic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE